News | Heart Valve Technology | November 02, 2018

Valve Replacement Volume Key to Successful Patient Outcomes

New study finds patient outcomes are best at healthcare facilities that perform high volumes of both surgical and transcatheter aortic valve replacements

Valve Replacement Volume Key to Successful Patient Outcomes

November 2, 2018 — Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to adopt a newer, less invasive technique, according to a new study, published Oct. 31 in JAMA Cardiology from Weill Cornell Medicine.1 When hospitals have a high caseload of both, they are likely to achieve the best patient outcomes for those who undergo the newer procedure.

“You can imagine that hospitals known for valve care are more likely to attract valve patients and adopt TAVR [transcatheter aortic valve replacement] more quickly,” said senior author Art Sedrakyan, M.D., Ph.D., a professor of healthcare policy and research at Weill Cornell Medicine. “And it’s likely that the more experience the hospitals have in performing valve surgery, the better patient outcomes are.”

In the study, the investigators sought to examine the relationship between the number of times hospitals perform the established procedure, called surgical aortic valve replacement (SAVR), and patient outcomes from the less invasive TAVR. TAVR has gained popularity in recent years, as it allows surgeons to deliver a valve replacement using only a catheter. TAVR was first approved in 2011 for high-risk patients who were considered inoperable.

Recently, the Centers for Medicare & Medicaid Services (CMS) set criteria to promote high-quality implementation of TAVR, including the requirement that hospitals perform at least 50 SAVR procedures a year prior to beginning TAVR procedures. Due to scrutiny over the requirements, a Medicare Evidence Development & Coverage Advisory Committee panel took place in July to discuss the issue. While some attendees argued for lowering the requirements, as they are difficult to reach in less populated areas, others posited that hospitals with high SAVR numbers would have lower complication rates for TAVR.

To discern that relationship, the Weill Cornell Medicine team, led by Sedrakyan, analyzed more than 60,000 TAVR procedures performed at hospitals between 2011 and 2015. They ultimately found that high volumes of both procedures was associated with the best outcomes for TAVR.

“It’s important that we evaluate TAVR and SAVR in a conjoined way. That’s what makes this study novel – previous studies have not assessed the effect of SAVR volume,” said first author Jialin Mao, M.D., an instructor in healthcare policy and research at Weill Cornell Medicine.

When researchers looked at patient mortality rates 30 days and then one year after undergoing TAVR, they found that patients treated at hospitals with high SAVR volume and high TAVR volume had the lowest mortality. “Patients need to know that getting care at institutions with the highest volume of aortic valve interventional care is most beneficial to them,” Sedrakyan said.

The findings suggest that federal requirements determining hospital eligibility for Medicare and Medicaid reimbursement for TAVR procedures are appropriate and could even be more restrictive.

“Current restrictions need to be maintained and made even stronger,” Sedrakyan said. “We don’t believe the time is right for widespread access to these technologies at the expense of patient safety.”

For more information: www.jamanetwork.com/journals/jamacardiology

Reference

1. Mao J., Redberg R.F., Carroll J.D., et al. Association Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes. JAMA Cardiology, published online Oct. 31, 2018. doi:10.1001/jamacardio.2018.3562

Related TAVR Content

Higher Volume of TAVR Boosts Key In-Hospital Outcomes

VIDEO: Impact of TAVR Procedural Volume on Patient Outcomes at ACC.16


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now